Not recruiting
Hormone receptor positive breast cancer+1
Not recruitingStudy Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy
Registered drugNo placebo
Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy
Registered drugNo placebo
- Disease:Hormone receptor positive breast cancerHormone receptor negative HER2 positive breast cancer
- Substances:AntipsychoticsCapecitabine+7
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Antipsychotics
